Loading clinical trials...
Loading clinical trials...
A Multi-center, Randomized, Double-blind (Sponsor Open), Placebo-controlled, Repeat-dose, Proof of Mechanism Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Explore Efficacy of GSK2330811 in Participants With Diffuse Cutaneous Systemic Sclerosis
Conditions
Interventions
GSK2330811
Placebo
Locations
14
United States
GSK Investigational Site
Los Angeles, California, United States
GSK Investigational Site
Stanford, California, United States
GSK Investigational Site
Chicago, Illinois, United States
GSK Investigational Site
Baltimore, Maryland, United States
GSK Investigational Site
Boston, Massachusetts, United States
GSK Investigational Site
Ann Arbor, Michigan, United States
Start Date
June 5, 2017
Primary Completion Date
July 7, 2020
Completion Date
July 7, 2020
Last Updated
May 24, 2021
NCT05878717
NCT06256575
NCT04319120
NCT06697561
NCT03559465
NCT05961267
Lead Sponsor
GlaxoSmithKline
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions